This study aims to test a new drug called CBI-1214 for people with a type of colon cancer called advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer. The study will check how safe the drug is, how well people can tolerate it, how the body processes it (pharmacokinetics), and if it can help fight the cancer (anti-tumor activity).
Participants must have specific types of cancer, and those who have already tried certain treatments without success can join. They must provide a sample of their cancer tissue. However, if someone has genetic markers called dMMR or MSI-H, past transplants, untreated brain cancer, recent serious infections, or certain heart or autoimmune diseases, they cannot join the study.
- Study Participation: Only those who have tried other treatments without success can join.
- Health Requirements: Participants must not have certain infections or serious health conditions.
- Tissue Sample: Participants need to provide a sample of their cancer tissue.